Clinical Research Directory

Key Inclusion Criteria 1. Eligible participants for this program consist of adults who have completed the End of Study (EOS) visit in the parent phase 1 study, R5458-668-ALG-2219 (NCT06369467) 2. Administration of first dose of EAP dupilumab occurs as defined in the protocol Key Exclusion Criteria 1. Participants who, during the parent study (R5458-668-ALG-2219 \[NCT06369467\]), developed a Serious Adverse Event (SAE) and/or Adverse Event (AE) as defined in the protocol 2. Any temporary discontinuation of study drug dupilumab lasting \>2 weeks during the parent study R5458-668-ALG-2219 (NCT06369467) 3. Greater than 2 weeks since last administration of study drug dupilumab from the parent study R5458-668-ALG-2219 (NCT06369467) NOTE: Other protocol defined inclusion/exclusion criteria apply.